Starpharma Holdings Ltd (ASX: SPL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Starpharma Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $40.56 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 417.37 million
Earnings per share -0.022
Dividend per share N/A
Year To Date Return -44.12%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Starpharma Holdings Ltd (ASX: SPL)
    Latest News

    A man looks down with fright as he falls towards the ground.
    Share Fallers

    3 ASX All Ords shares tumbling into the weekend

    This trio of All Ords shares has had a shocker today...

    Read more »

    Rising arrow on a blue graph symbolising a rising share price.
    Healthcare Shares

    Starphama share price lunges 5% on product relaunch

    Early support for Starphama on Thursday has it off to a great start.

    Read more »

    A group of science or medical professionals cheering good news in the lab.
    Healthcare Shares

    Here's why the Starpharma (ASX:SPL) share price is having such a stellar end to the week

    The global biopharmaceutical company has great news for ASX investors today.

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    4 ASX healthcare shares at 52-week lows

    A number of ASX healthcare shares just hit 52-week lows.

    Read more »

    Scientists in white coats look disappointed as the Starpharma share price falls today
    Healthcare Shares

    Here's why the Starpharma (ASX:SPL) share price is tumbling 8% today

    Starpharma has responded to a media article published today.

    Read more »

    Two happy scientists analysing test results.
    Healthcare Shares

    Starpharma (ASX:SPL) share price lifts on Omicron study results

    Omicron has been dealt another blow thanks to Starphama's latest study results.

    Read more »

    A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
    Share Market News

    Not enough: Starpharma (ASX:SPH) share price plunges despite 200% revenue growth

    Starpharma shares closed in the red on Monday as the company released its financial results for the half-year ended 31…

    Read more »

    A medical researcher in a white coat holds laboratory equipment and smiles.
    Healthcare Shares

    What is happening to the Starpharma (ASX:SPL) share price today?

    Starpharma is complementing COVID-19 vaccines with its anti-viral nasal spray

    Read more »

    A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
    Healthcare Shares

    Starpharma (ASX:SPL) share price shoots 6% higher on Roche agreement

    The company's shares are on the move today.

    Read more »

    A young woman wearing glasses and a red top looks at her laptop smiling
    Healthcare Shares

    Starpharma (ASX:SPL) share price climbs 3% on back of Vietnam launch

    What's happening with the biopharmaceutical company?

    Read more »

    A graphic image of three upward pointing arrows with smoke coming from their bottoms, indicating the arrows are taking off just like the Althea share price today
    Share Gainers

    Why Bellevue Gold, South32, Starpharma, and Tuas shares are pushing higher

    These ASX shares are on form on Wednesday...

    Read more »

    Starpharma share price A doctor or medical expert in COVID-19 protection flexes his muscle, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    The Starpharma (ASX: SPL) share price surges on Vietnam launch

    The Starpharma Holdings Limited (ASX: SPL) share price is racing ahead this morning after confirming its antiviral nasal spray will…

    Read more »

    Frequently Asked Questions

    No, Starpharma does not pay dividends at this time.

    Starpharma listed on the ASX on 28 September 2000.

    SPL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Starpharma Holdings Ltd

    Starpharma Holdings Ltd (ASX: SPL) is an Australian biotechnology company involved in the development of dendrimer products for pharmaceutical, life science, and other applications.

    Dendrimers are synthetically manufactured, nanoscale molecules, particularly useful to the pharmaceutical industry for their unique properties as carriers of other molecular structures.

    Starpharma describes itself as a world leader in the field. The company is developing programs for drug delivery applications, the treatment of respiratory viruses, and its VivaGel product.

    VivaGel can be used for the management and prevention of bacterial vaginosis and as a coating for condoms. The company's VIRALEZE product is an antiviral nasal spray approved for use in many countries, including Europe and the UK.

    SPL Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Nov 2024 $0.10 $0.00 0.00% 1,972,692 $0.10 $0.10 $0.10
    31 Oct 2024 $0.09 $0.01 11.24% 2,106,773 $0.09 $0.09 $0.09
    30 Oct 2024 $0.09 $0.00 0.00% 404,352 $0.09 $0.09 $0.09
    29 Oct 2024 $0.09 $0.00 0.00% 18,258 $0.09 $0.09 $0.09
    28 Oct 2024 $0.09 $0.00 0.00% 430,682 $0.09 $0.09 $0.09
    25 Oct 2024 $0.09 $0.00 0.00% 249,146 $0.09 $0.09 $0.09
    24 Oct 2024 $0.09 $0.00 0.00% 169,487 $0.09 $0.09 $0.09
    23 Oct 2024 $0.09 $0.00 0.00% 51,019 $0.09 $0.09 $0.09
    22 Oct 2024 $0.09 $0.00 0.00% 1,183,910 $0.09 $0.09 $0.09
    21 Oct 2024 $0.09 $0.00 0.00% 3,101,661 $0.09 $0.09 $0.09
    18 Oct 2024 $0.09 $0.00 0.00% 2,290,747 $0.09 $0.09 $0.09
    17 Oct 2024 $0.09 $0.00 0.00% 224,841 $0.10 $0.10 $0.09
    16 Oct 2024 $0.10 $0.00 0.00% 6,815 $0.10 $0.10 $0.10
    15 Oct 2024 $0.10 $0.00 0.00% 30,993 $0.10 $0.10 $0.10
    14 Oct 2024 $0.10 $0.00 0.00% 106,140 $0.10 $0.10 $0.10
    11 Oct 2024 $0.10 $0.00 0.00% 58,166 $0.10 $0.10 $0.10
    10 Oct 2024 $0.10 $0.00 0.00% 58,836 $0.10 $0.10 $0.10
    09 Oct 2024 $0.10 $0.00 0.00% 3,773,632 $0.10 $0.10 $0.10
    08 Oct 2024 $0.10 $0.00 0.00% 2,903 $0.10 $0.10 $0.10
    07 Oct 2024 $0.10 $0.00 0.00% 31,879 $0.10 $0.10 $0.10
    04 Oct 2024 $0.10 $0.00 0.00% 364,089 $0.10 $0.10 $0.10

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    23 Oct 2024 Robert Thomas Buy 300,000 $27,750
    On-market trade.
    23 Oct 2024 Robert Thomas Buy 200,000 $18,500
    On-market trade.
    13 Sep 2024 Russell Basser Buy 200,000 $18,600
    On-market trade.
    02 Sep 2024 David McIntyre Buy 405,886 $3,879
    On-market trade. As per announcement on 02-09-2024
    02 Sep 2024 Robert Thomas Buy 350,000 $3,246
    On-market trade.
    28 Jun 2024 Jeff Davies Buy 879,687 $79,699
    On-market trade.
    26 Jun 2024 Robert Thomas Buy 200,000 $17,800
    On-market trade.
    25 Jun 2024 Lynda Cheng Buy 110,555 $9,950
    On-market trade.
    20 Jun 2024 Robert Thomas Buy 250,000 $22,679
    On-market trade.
    30 May 2024 Cheryl Maley Buy 125,000 $14,065
    On-market trade.
    29 May 2024 Robert Thomas Buy 150,000 $17,750
    On-market trade.
    15 Apr 2024 Robert Thomas Buy 100,000 $13,000
    On-market trade.
    12 Apr 2024 Russell Basser Buy 71,428 $10,002
    On-market trade.
    10 Apr 2024 Robert Thomas Buy 250,000 $43,424
    On-market trade.
    08 Dec 2023 Jacinth (Jackie) Fairley Issued 667,441 $90,104
    Issue of securities. 6,432,648 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Robert Bain Thomas Non-Executive DirectorNon-Executive Chairman Dec 2013
    Mr Thomas has background in financial services and capital markets and is a non-executive director of several Australian listed companies. He was previously a Partner of Potter Partners (now UBS), where he was also Head of Research. He is a member of Risk Committee.
    Ms Cheryl Ann Maley Chief Executive OfficerManaging Director Jan 2024
    Ms Maley has over 25 years of experience in the pharmaceutical industry, including 20 years in leadership roles at well-known and leading organisations, including Novartis and AbbVie. Her previous roles include nine years at Novartis in senior commercial and executive roles and various sales and marketing positions with AbbVie/Abbott, Servier Laboratories, and Wyeth Pharmaceuticals.
    Mr David McIntyre Non-Executive Director Mar 2020
    Mr McIntyre has more than 20 years of executive experience including 18 years in the life sciences sector, having held various C-suite level roles at Tessa Therapeutics, Inc., AVITA Therapeutics, Inc., HeartWare International, Inc., and Braeburn, Inc. He is the Chair of Risk Committee.
    Ms Lynda Cheng Non-Executive Director Aug 2021
    Ms Cheng has over 25 years of experience as a finance executive, including substantial international experience and several non-executive directorships, Ms Cheng's experience covers the majority of key areas described in Starpharma's Board skills matrix. In particular, she has expertise in accounting/corporate finance, audit and risk; M&A/capital markets; strategy and risk management; governance; as well as business development. Ms Cheng has had involvement in the commercialisation of new innovations during her tenure at South East Water and also while working with disruptive technology companies in Silicon Valley. She is a member of Risk Committee.
    Dr Jeff Davies Non-Executive Director Apr 2022
    Dr Davies has over 35 years of experience within the biopharmaceutical industry, Dr Davies is an accomplished executive skilled in R&D, product development and commercialisation strategy, business development, manufacturing and clinical and regulatory affairs. Dr Davies has leadership skills and experience in commercialising scientific research for healthcare products.
    Dr Russell Basser Non-Executive Director Feb 2023
    Dr Basser has over 20 years of executive experience in the biotechnology industry and 10 years as a practicing clinical oncologist, Dr Basser has leadership skills and experience in healthcare/scientific research; pharmaceutical product development; international executive experience and skills in regulation/public policy; commercialisation of innovation; business development; governance; strategy; and risk management.
    Mr Justin Cahill Chief Financial OfficerCompany Secretary Apr 2023
    -
    Justin Cahill Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 81,247,474 19.70%
    JP Morgan Nominees Australia PTY Limited 31,174,308 7.56%
    Citicorp Nominees Pty Limited 15,203,959 3.69%
    BNP Paribas Noms Pty Ltd 14,494,331 3.51%
    Bell Potter Nominees Ltd <Bb Nominees A/C> 9,000,000 2.18%
    Ingot Capital Investments Pty Ltd 8,705,000 2.11%
    T & N Argyrides Investments P/L <T & N Argyrides Pension A/C> 5,060,000 1.23%
    BNP Paribas Nominees Pty Ltd <Clearstream> 4,866,370 1.18%
    Mr Kingsley Bryan Bartholomew 4,612,025 1.12%
    Lavya Pty Ltd <Lavya Family A/C> 4,344,628 1.05%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 4,267,008 1.03%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,141,107 1.00%
    Mr Peter Murray Jackson 3,921,959 0.95%
    E Equities Pty Ltd 3,700,000 0.90%
    All States Finance Pty Limited 3,500,000 0.85%
    Applecross Secretarial Services Pty Ltd <L Gorr Family A/C> 3,361,550 0.82%
    Ms Jacinth Fairley 3,252,386 0.79%
    Charles & Cornelia Goode Foundation Pty Ltd <CCG Foundation A/C> 3,200,000 0.78%
    Mr Thomas Argyrou 3,000,000 0.73%
    BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> 2,739,822 0.66%

    Profile

    since

    Note